Myeloproliferative Neoplasms News

ASH announced the election of three clinicians to leadership positions within the society.

ASH awarded $150,000 each to 19 investigators through the society’s bridge grant program, designed to sustain promising hematologic research proposals that are not funded through NIH.

BARCELONA — The International Association for the Study of Lung Cancer, or IASLC, today issued a declaration at its World Conference on Lung Cancer advising all physicians to screen their patients with cancer for tobacco use and recommend tobacco cessation.

Individuals with a child, parent or sibling with a hematologic malignancy may be at higher risk for being diagnosed with the same disease, according to results of a retrospective study published in Blood.

The FDA today approved fedratinib for the treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis.

The FDA has issued a class 1 recall — the most serious kind of recall — of Qiagen’s pipetting system filter tips. The recall affects 1,269,760 tips in 1,240 kits that are used to monitor antiviral treatment in patients with cytomegalovirus or to evaluate patients for myeloproliferative neoplasms.

Several distinguished leaders in hematology will be honored with awards and special lectures at this year’s ASH Annual Meeting and Exposition, scheduled for Dec. 7-10 in Orlando, Florida.

Esther Obeng, MD, PhD, received the 2019 Gertrude B. Elion Cancer Research Award from American Association for Cancer Research.

Guadecitabine demonstrated clinical activity with acceptable toxicity among patients with intermediate- and high-risk myelodysplastic syndrome, according to randomized phase 2 trial results published in The Lancet Haematology.

Dana-Farber Cancer Institute opened a new clinic designed to improve clinical care and monitoring for individuals with precursor conditions that can progress to blood cancers.